Logo

LEO Pharma' Adtralza (tralokinumab) Receives EC's Approval for Moderate-To-Severe Atopic Dermatitis

Share this

LEO Pharma' Adtralza (tralokinumab) Receives EC's Approval for Moderate-To-Severe Atopic Dermatitis

Shots:

  • The approval is based on efficacy & safety results from the P-III ECZTRA 1- 2 & 3 trials which evaluates Adtralza (300mg- SC) as monthx vs PBO in 1900+ adult patients with a mod. to sev. AD who are candidates for systemic therapy
  • Results: improvement in signs & symptoms with treatment response rates gradually improved & maintained over time- was generally well tolerated with an overall frequency & severity of AEs & reduce itch- improve QoL
  • The EC decision is valid in all EU member states- Iceland- Norway & Liechtenstein while regulatory filings are ongoing with MHRA in the UK & other health authorities globally. The approval marks the 1st high-affinity mAb approved therapy to inhibit IL-13 cytokine

  | Ref: Business Wire | Image: Berlingske

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions